![]() ![]() The Listener’s Guide to all things X-Ray Vision!Ĭonsider donating to the Entertainment Community Fund here. ![]() Send a short pitch and 2-3 minute voice memo recording to that answers the following questions: 1) How did you get into/discover your ‘Nerd Out?’ (2) Why should we get into it too? (3) What’s coming soon in this world that we can look forward to or where can we find it? If you’re sending a theory, feel free to send only a summary of your theory (no audio needed) for Jason and Rosie to react to on air.įollow Rosie: IG, Letterboxd, & newsletter Tune in every Wednesday & Friday and don’t forget to Hulk Smash the Follow button! Thank you for your patience as we work to resolve this issue. Note: Imprecise timestamps are an unfortunate side effect of a new ads system. In the Hive Mind (1:05:34), Guardians of the Galaxy franchise co-star Sean Gunn joins to discuss the end of the trilogy, his working relationship with his brother James, Kraglin’s character development, and more. Then, Jason and Zig discuss their experiences with the WGA Writers Strike so far. nodal extra-capsular extension (ECE) and positive resection margins (R1 or close margin less than or equal to (= 2 audiometric hearing loss or tinnitus Grade >= 2.On this episode of X-Ray Vision, Jason Concepcion, Rosie Knight, and Cody Ziglar enter Hyrule! In the Airlock (1:43), they dive deep (deeep) into video games, predominantly Breath of the Wild and the newly released follow-up Tears of the Kingdom, along with what other games they’ve been enjoying.Participants with no residual disease by computed tomography (CT) or magnetic resonance imaging (MRI) and have a high risk of relapse with 1 or 2 of the following criteria, confirmed by local histopathology:.Oropharynx (OPC) participants must have known human papillomavirus (HPV) status as determined by p16 expression using immunohistochemistry (ICH).Participants have received surgery with curative intent on these sites in the past 4 to 8 weeks before start of treatment (Cycle 1 Day 1) Participants with histologically confirmed squamous cell carcinoma with one of the following primary sites: oral cavity, oropharynx, hypopharynx or larynx.Participants with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1.Change from Baseline in EuroQOL 5 Dimension 5 Level Health-Related Quality of Life Measure Visual Analog Scale Score (EQ-5D-5L VAS) and End of treatment (at Week 20) ]. ![]() Change from Baseline in European Organization for research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) Score and End of treatment (at Week 20) ].Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN35) Score and End of treatment (at Week 20) ].Number of Participants with Adverse Events (AEs) and Treatment-related AEs.Condition or diseaseĭrug: Xevinapant (Debio 1143) Radiation: IMRT Drug: Placebo Visit frequency: Weekly visit during combination therapy period, once every 3 weeks during monotherapy period, and every 3, 4, or 6 months during the Disease-Free Survival Follow-up period in Year 1, 2 and 3, or 4 and 5 (with telephone contact in between), respectively, and every 3 months (telephone visits allowed) during the Overall Survival Follow-up period. Health measurement/observation: Improved Disease-Free Survival. Treatment duration: 18 weeks, consisting of six 3-week cycles. Study details include: Study duration: Participants will be followed until the last on-study participant reaches his/her 60-month post-randomization visit, a decision to end the study has been triggered, or until premature discontinuation from study, whichever occurs first. The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are ineligible to receive cisplatin-based chemoradiation concurrently. Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |